Beyne İlaç Taşınması ve Dağılımının Farmakokinetiği

Yıl 2017, Sayı: 2, 81 - 104, 01.06.2017

Tuğba Çopur Sibel Bozdağ Pehlivan Levent Öner

Öz

Merkezi Sinir Sistemi MSS hastalıklarının sıklığında son zamanlarda ciddi bir artış görülmesi, bu alanda daha etkili ve güvenli tedaviler geliştirilmesi gerekliliğine yol açmıştır. İlaç keşfi ve geliştirilmesi çalışmalarında karşılaşılan en büyük zorluklardan biri beyinde etkili ve güvenli konsantrasyon profilinin elde edilmesidir. Farmakolojik etkinin ortaya çıkabilmesi için MSS ilaçlarının kan beyin engelini KBE geçmesi, hedef bölgeye etkili konsantrasyonlarda ulaşması ve ilacın serbest fraksiyonunun hedef ile uygun bir şekilde etkileşmesi gerekir. Serebral kan akım hızı F , KBE’nin permeabilitesi influks klerensi , ilacın fizikokimyasal özellikleri, beyin dokusuna nonspesifik bağlanma derecesi ve efluks klerensi beyne ilaç taşınmasında etkili olan temel faktörlerdir. Aktif influks ve/veya efluks taşıyıcılar da ilaçların mutlak beyin konsantrasyonunu etkiler. İlacın kan-beyin arasındaki dengelenme hızı CLin, Kin , dengelenme derecesi Kp,uu,beyin ve beyin içi dağılımı Vu,beyin ; beyinde etkili konsantrasyonlara ulaşıp ulaşmadığını doğrulamak için tespit edilmesi gereken başlıca parametrelerdir. Bu parametrelerin belirlenmesi için in vitro, in vivo ve in siliko yöntemler kullanılmaktadır.

Anahtar Kelimeler

Kan-beyin engeli, beyne ilaç taşınması, farmakokinetik

Pharmacokinetics of Brain Drug Delivery and Distribution

Öz

Recently, significant increases in the frequency of central nervous system CNS diseases have led to the need to develop more effective and safe therapies. One of the biggest challenges in drug discovery and development studies is obtained the effective and safe concentration profile in the brain. In order for pharmacologic efficacy to occur, CNS drugs must cross the bloodbrain barrier BBB , reach effective concentrations at the target site, and the free fraction of the drug should interact appropriately with the target. Cerebral blood flow F , permeability of BBB influx clearance , physicochemical properties of the drug, nonspecific binding level to the brain tissue and efflux clearance are the main factors that are effective in drug delivery to the brain. Active influx and/or efflux carriers also affect the absolute brain concentration of the drugs. The drug equilibrium rate CLin, Kin and the drug equilibrium extent Kp,uu,brain between blood to brain and intracerebral distribution of the drug Vu,brain are the main parameters which should be determined in order to verify whether the drug has reached effective concentrations in the brain or not. In vivo, in vitro and in silico methods are being used for the determination of such parameters.

Anahtar Kelimeler

Blood-brain barrier, brain drug delivery, pharmacokinetics

Kaynakça

• Hurko O, Ryan J: Translat onal research n central nervous system drug d scovery. Neurotherapeut cs 2005, 2(4):671-682.
• Pangalos MN, Schechter LE, Hurko O: Drug development for CNS d sorders: Strateg es for balanc ng r sk and reduc ng attr t on. Nature Rev ews Drug D scovery 2007, 6(7):521-532.
• Re chel A: Address ng central nervous system (CNS) penetrat on n drug d scovery: Bas cs and mpl cat ons of the evolv ng new concept. Chem stry & B od vers ty 2009, 6(11):2030-2049.
• Zlokov c BV: The blood-bra n barr er n health and chron c neurodegenerat ve d sorders. Neuron
• W ttchen HU, Jacob F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al: The s ze and burden of mental d sorders and other d sorders of the bra n n Europe 2010. European Neuropsychopharmacology 2011, 21(9):655-679.
• Pardr dge WM: Drug and gene del very to the bra n: The vascular route. Neuron 2002, 36(4):555-558.
• Hammarlund-Udenaes M, Bredberg U, Fr den M: Methodolog es to assess bra n drug del very n lead opt m zat on. Current Top cs n Med c nal Chem stry 2009, 9(2):148-162.
• Hammarlund-Udenaes M: Act ve-s te concentrat ons of chem cals – Are they a better pred ctor of effect than plasma/organ/t ssue concentrat ons? Bas c & Cl n cal Pharmacology & Tox cology 2010, 106(3):215-220.
• Loryan I, S nha V, Mack e C, Van Peer A, Dr nkenburg W, Vermeulen A, et al: Mechan st c understand ng of bra n drug d spos t on to opt m ze the select on of potent al neurotherapeut cs n drug d scovery. Pharmaceut cal Research 2014, 31(8):2203-2219.
• Hammarlund-Udenaes M, Fr dén M, Syvänen S, Gupta A: On the rate and extent of drug del very to the bra n. Pharmaceut cal Research 2008, 25(8):1737-1750.
• Hammarlund-Udenaes M. Pharmacok net c Concepts n Bra n Drug Del very. In: Hammarlund- Udenaes M, de Lange ECM, Thorne RG (eds), Drug Del very to the Bra n. Spr nger, Berl n, Germany. 2014:127-161.
• Re chel A. Pharmacok net cs of CNS Penetrat on. In: L D EHK (eds), Blood-Bra n Barr er n Drug D scovery: Opt m z ng Bra n Exposure of CNS Drugs and M n m z ng Bra n S de Effects for Per pheral Drugs. John W ley & Sons, New York, USA. 2015:10-16.
• Re chel A: The role of blood-bra n barr er stud es n the pharmaceut cal ndustry. Current Drug Metabol sm 2006, 7(2):183-203.
• Summerf eld SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, et al: Toward an mproved pred ct on of human n v vo bra n penetrat on. Xenob ot ca 2008, 38(12):1518-1535.
• Summerf eld S, Dong K: In v tro, n v vo and n s l co models of drug d str but on nto the bra n. Journal of Pharmacok net cs and Pharmacodynam cs 2013, 40(3):301-314.
• L u X, Cheong J, D ng X, Deshmukh G: Use of cassette dos ng approach to exam ne the effects of p-glycoprote n on the bra n and cerebrosp nal flu d concentrat ons n w ld-type and p-glycoprote n knockout rats. Drug Metabol sm and D spos t on 2014, 42(4):482-491.
• Denn son JE, Andersen ME, Clewell HJ, Yang RSH: Development of a phys olog cally based pharmacok net c model for volat le fract ons of gasol ne us ng chem cal lump ng analys s. Env ronmental Sc ence & Technology 2004, 38(21):5674-5681.
• Garberg P, Ball M, Borg N, Cecchell R, Fenart L, Hurst RD, et al: In v tro models for the blood– bra n barr er. Tox cology In V tro 2005, 19(3):299-334.
• Summerf eld SG, Read K, Begley DJ, Obradov c T, H dalgo IJ, Coggon S, et al: Central nervous system drug d spos t on: The relat onsh p between n s tu bra n permeab l ty and bra n free fract on. Journal of Pharmacology and Exper mental Therapeut cs 2007, 322(1):205-213.
• A bbott NJ, Dolman DEM, Patabend ge AK: Assays to pred ct drug permeat on across the blood- bra n barr er, and d str but on to bra n. Current Drug Metabol sm 2008, 9(9):901-910.
• Summerf eld S, Jeffrey P: D scovery DMPK: Chang ng parad gms n the e ght es, n net es and nought es. Expert Op n on on Drug D scovery 2009, 4(3):207-218.
• Re chel A. Integrated Approach to Opt m z ng CNS Penetrat on n Drug D scovery: From the Old to the New Parad gm and Assessment of Drug–Transporter Interact ons. In: Hammarlund- Udenaes M, de Lange ECM, Thorne RG(eds), Drug Del very to the Bra n. Spr nger, Berl n, Germany. 2014: 339-374.
• Wold S: Val dat on of QSAR's. Quant tat ve Structure-Act v ty Relat onsh ps 1991, 10(3):191-193.
• Begley D, Br ghtman M. Structural and Funct onal Aspects of the Blood-Bra n Barr er. In: Proka L, Proka -Tatra K (eds), Pept de Transport and Del very nto the Central Nervous System. B rkhäuser, Basel, Sw tzerland. 2003:39-78.
• Abbott NJ: Ev dence for bulk flow of bra n nterst t al flu d: S gn f cance for phys ology and pathology. Neurochem stry Internat onal 2004, 45(4):545-552.
• Abbott NJ: Pred ct on of blood–bra n barr er permeat on n drug d scovery from n v vo, n v tro and n s l co models. Drug D scovery Today: Technolog es 2004, 1(4):407-416.
• Abbott NJ, Ronnback L, Hansson E: Astrocyte-endothel al nteract ons at the blood-bra n barr er. Nature Rev ews Neurosc ence 2006, 7(1):41-53.
• Cecchell R, Berezowsk V, Lundqu st S, Culot M, Renftel M, Dehouck M-P, et al: Modell ng of the blood-bra n barr er n drug d scovery and development. Nature Rev ews Drug D scovery 2007, 6(8):650-661.
• Abbott NJ: Blood–bra n barr er structure and funct on and the challenges for CNS drug del very. Journal of Inher ted Metabol c D sease 2013, 36(3):437-449.
• B cker J, Alves G, Fortuna A, Falcão A: Blood–bra n barr er models and the r relevance for a successful development of CNS drug del very systems: A rev ew. European Journal of Pharmaceut cs and B opharmaceut cs 2014, 87(3):409-432.
• R sau W. Molecular B ology of Blood-Bra n Barr er Ontogenes s and Funct on. In: Ito U (eds), Bra n Edema IX. Spr nger, Berl n, Germany. 1994:109-112.
• Pardr dge WM: CNS drug des gn based on pr nc ples of blood-bra n barr er transport. Journal of Neurochem stry 1998, 70(5):1781-1792.
• Kreuter J: Transport of drugs across the blood-bra n barr er by nanopart cles. Current Med c nal Chem stry -Central Nervous System Agent 2002, 2(3):241-249.
• Begley DJ: Del very of therapeut c agents to the central nervous system: The problems and the poss b l t es. Pharmacology & Therapeut cs 2004, 104(1):29-45.
• L u X, Chen C: Strateg es to opt m ze bra n penetrat on n drug d scovery. Current Op n on n Drug D scovery & Development 2005, 8(4):505-512.
• L u X, Sm th BJ, Chen C, Callegar E, Becker SL, Chen X, et al: Use of a phys olog cally based pharmacok net c model to study the t me to reach bra n equ l br um: An exper mental analys s of the role of blood-bra n barr er permeab l ty, plasma prote n b nd ng, and bra n t ssue b nd ng. Journal of Pharmacology and Exper mental Therapeut cs 2005, 313(3):1254-1262.
• Ja n KK. An Overv ew of Drug Del very to the CNS. In: Ja n KK (eds), Drug Del very to the Central Nervous System. Humana Press,New York C ty, USA. 2010: 1-13.
• Copur T, Oner L. Drug Del very to the Bra n: Pharmacok net c Concepts. In: Gürsoy-Ozdem r Y, Bozdag-Pehl van S, Sekerdag E (eds), Nanotechnology Methods for Neurolog cal D seases and Bra n Tumors: Drug Del very Across the Blood-Bra n Barr er. Elsev er, (In Press 2017).
• Wong A, Ye M, Levy A, Rothste n J, Bergles D, Searson PC: The blood-bra n barr er: An eng neer ng perspect ve. Front ers n Neuroeng neer ng 2013, 6(7):1-22.
• K m SY, Buckwalter M, Soreq H, Vezzan A, Kaufer D: Blood-bra n barr er dysfunct on- nduced nflammatory s gnal ng n bra n pathology and ep leptogenes s. Ep leps a 2012, 53(Supplement 6):37-44.
• Wardlaw JM, Doubal FN, Valdes-Hernandez M, Wang X, Chappell FM, Shuler K, et al: Blood– 41. bra n barr er permeab l ty and long-term cl n cal and mag ng outcomes n cerebral small vessel d sease, Stroke 2013, 44(2):525-527.
• Tega Y, Akanuma S, Kuba Y, Terasak T, Hosaya K: Blood-to-bra n nflux transport of n cot ne at the rat blood bra n barr er: Involvement of a pyr lam ne-sens t ve organ c cat on transport process. Neurochem stry Internat onal 2013, 62(2):173-181.
• Kaffash A. Mal gn gl omların tedav s ç n l p t le şlevselleşt r lm ş PLGA nanopart küller n n tasarımı, n v tro ve n v vo değerlend r lmes [Yüksek l sans tez ]. Ankara: Hacettepe Ün vers tes ; 2013.
• Re ber H, Felgenhauer K: Prote n transfer at the blood cerebrosp nal flu d barr er and the quant tat on of the humoral mmune response w th n the central nervous system. Cl n ca Ch m ca Acta 1987, 163(3):319-328.
• Segal M: The choro d plexuses and the barr ers between the blood and the cerebrosp nal flu d. Cellular and Molecular Neurob ology 2000, 20(2):183-196.
• Pardr dge WM: Drug transport across the blood-bra n barr er. Journal of Cerebral Blood Flow & Metabol sm 2012, 32(11):1959-1972.
• Deo AK, The l F-P, N colas J-M: Confound ng parameters n precl n cal assessment of blood– bra n barr er permeat on: An overv ew w th emphas s on spec es d fferences and effect of d sease states. Molecular Pharmaceut cs 2013, 10(5):1581-1595.
• Dav es B, Morr s T: Phys olog cal parameters n laboratory an mals and humans. Pharmaceut cal Research 1993, 10(7):1093-1095.
• Pardr dge WM: Drug and gene target ng to the bra n w th molecular Trojan horses. Nature Rev ews Drug D scovery 2002, 1(2):131−139.
• Ganesh K, Quent n RS, M tsuh ko H, Jagan P, Mark WD: Bra n uptake, pharmacok net cs, and t ssue d str but on n the rat of neurotox c N-butylbenzenesulfonam de. Tox colog cal Sc ences 2007, 97(2):253-264.
• Begley DJ, Khan EU, Roll nson C, Abbott J. The Role of Bra n Extracellular Flu d Product on and Drug Transport to the Bra n. In: Begley DJ, Bradbury MW, Kreuter J (eds), The Blood-Bra n Barr er and Drug Del very to CNS. Marcel Dekker, Inc, New York, USA. 2000: 93−108.
• K melberg HK: Water homeostas s n the bra n: Bas c concepts. Neurosc ence 2004, 129(4):851-860.
• Westerhout J, Danhof M, De Lange ECM: Precl n cal pred ct on of human bra n target s te concentrat ons: Cons derat ons n extrapolat ng to the cl n cal sett ng. Journal of Pharmaceut cal Sc ences 2011, 100(9):3577-3593.
• Johanson CE, Duncan JA, 3rd, Kl nge PM, Br nker T, Stopa EG, S lverberg GD: Mult pl c ty of cerebrosp nal flu d funct ons: New challenges n health and d sease. Cerebrosp nal Flu d Research 2008, 5:10.
• Cserr H: Potass um exchange between cerebrosp nal flu d, plasma, and bra n. Journal of Phys ology Legacy Content 1965, 209(6):1219-1226.
• Osh o K, Watanabe H, Song Y, Verkman A S, Manley G T: Reduced cerebrosp nal flu d product on and ntracran al pressure n m ce lack ng choro d plexus water channel Aquapor n-1. The FASEB Journal 2005, 19(1):76−78.
• Eyal S, Ke B, Muz M, L nk JM, Mankoff DA, Coll er AC, et al: Reg onal p-glycoprote n act v ty and nh b t on at the human blood–bra n barr er as maged by pos tron em ss on tomography. Cl n cal Pharmacology & Therapeut cs 2010, 87(5):579-585.
• Stange K, Gre tz D, Ingvar M, H ndmarsh T, Sollev A: Global cerebral blood flow dur ng nfus on of adenos ne n humans: Assessment by magnet c resonance mag ng and pos tron em ss on tomography. Acta Phys olog ca Scand nav ca 1997, 160(2):117-122.
• Harash ma H, Sawada Y, Sug yama Y, Iga T, Hanano M: Analys s of nonl near t ssue d str but on of qu n d ne n rats by phys olog cally based pharmacok net cs. Journal of Pharmacok net cs and B opharmaceut cs 1985, 13(4):425-440.
• L nde R, Hasselbalch SG, Topp S, Paulson OB, Madsen PL: Global cerebral blood flow and metabol sm dur ng acute hyperketonem a n the awake and anesthet zed rat. Journal of Cerebral Blood Flow & Metabol sm 2006, 26(2):170-180.
• Sheng H, Laskow tz DT, Mackensen GB, Kudo M, Pearlste n RD, Warner DS: Apol poprote n E def c ency worsens outcome from global cerebral schem a n the mouse. Stroke 1999, 30(5):1118−1124.
• Itoh Y, Esak T, Cook M, Qasba P, Sh moj K, Alroy J, Brady RO, Sokoloff L, Moore DF: Local and global cerebral blood flow and glucose ut l zat on n the alpha-galactos dase A knockout mouse model of Fabry d sease. Journal of Neurochem stry 2001, 79(6):1217−1224.
• Jay TM, Luc gnan G, Crane AM, Jehle J, Sokoloff L: Measurement of local cerebral blood flow w th [14C] odoant pyr ne n the mouse. Journal of Cerebral Blood Flow & Metabol sm 1988, 8(1):121−129.
• Hammarlund-Udenaes M, Paalzow L, de Lange EM: Drug equ l brat on across the blood—bra n barr er-pharmacok net c cons derat ons based on the m crod alys s method. Pharmaceut cal Research 1997, 14(2):128-134.
• Syvänen S, X e R, Sah n S, Hammarlund-Udenaes M: Pharmacok net c consequences of act ve drug efflux at the blood–bra n barr er. Pharmaceut cal Research 2006, 23(4):705-717.
• Rowland MT: Cl n cal pharmacok net cs and pharmacodynam cs: Concepts and appl cat ons. Wolters Kluwer/L pp ncott W ll ams & W lk ns 2011:159-176.
• Bulat M, Ž vkov ć B. Neurochem cal Study of the Cerebrosp nal Flu d. In: Marks N, Rodn ght R (eds), Research Methods n Neurochem stry. Spr nger, Berl n, Germany. 1978:57-89.
• Ph ll pson M, Kaur J, Colarusso P, Ballantyne CM, Kubes P: Endothel al domes encapsulate adherent neutroph ls and m n m ze ncreases n vascular permeab l ty n paracellular and transcellular em grat on. PLoS ONE 2008, 3(2):1-8.
• Serl n Y, Shelef I, Knyazer B, Fr edman A: Anatomy and phys ology of the blood–bra n barr er. Sem nars n Cell & Developmental B ology 2015, 38:2-6.
• Palmer AM, Alav jeh MS: Overv ew of exper mental models of the blood‐bra n barr er n CNS drug d scovery. Current Protocols n Pharmacology 2013, 7-15.
• Vorbrodt AW, Dobrogowska DH: Molecular anatomy of ntercellular junct ons n bra n endothel al and ep thel al barr ers: Electron m croscop st’s v ew. Bra n Research Rev ews 2003, 42(3):221-242.
• Bhowm k A, Khan R, Ghosh MK: Blood bra n barr er: A challenge for effectual therapy of bra n tumors. B oMed Research Internat onal 2015: 2015-2020.
• Kaya M, Becker AJ, Gürses C: Blood–bra n barr er, ep leptogenes s, and treatment strateg es n cort cal dysplas a. Ep leps a 2012, 53(6):31-36.
• F scher H, Gottschl ch R, Seel g A: Blood-bra n barr er permeat on: Molecular parameters govern ng pass ve d ffus on. The Journal of Membrane B ology 1998, 165(3):201-211.
• Crone C: The permeab l ty of bra n cap llar es to non-electrolytes. Acta Phys olog ca Scand nav ca 1965, 64(4):407-417.
• Ferguson R, Woodbury D: Penetrat on of 14C- nul n and 14C-sucrose nto bra n, cerebrosp nal flu d, and skeletal muscle of develop ng rats. Exper mental Bra n Research 1969, 7(3):181-194.
• Ohno K, Pett grew K, Rapoport S: Lower l m ts of cerebrovascular permeab l ty to nonelectrolytes n the consc ous rat. Amer can Journal of Phys ology-Heart and C rculatory Phys ology 1978, 235(3):299-307.
• H tchcock SA, Penn ngton LD: Structure−bra n exposure relat onsh ps. Journal of Med c nal Chem stry 2006, 49(26):7559-7583.
• Kreuter J: Nanopart culate systems for bra n del very of drugs. Advanced Drug Del very Rev ews 2001, 47(1):65-81.
• Gabathuler R: Approaches to transport therapeut c drugs across the blood–bra n barr er to treat bra n d seases. Neurob ology of D sease 2010, 37(1):48-57.
• L p nsk CA, Lombardo F, Dom ny BW, Feeney PJ: Exper mental and computat onal approaches to est mate solub l ty and permeab l ty n drug d scovery and development sett ngs. Advanced Drug Del very Rev ews 1997, 23(1-3):3-25.
• Chen Y, L u L: Modern methods for del very of drugs across the blood–bra n barr er. Advanced Drug Del very Rev ews 2012, 64(7):640-665.
• Nagpal K, S ngh SK, M shra DN: Drug target ng to bra n: A systemat c approach to study the factors, parameters and approaches for pred ct on of permeab l ty of drugs across BBB. Expert Op n on on Drug Del very 2013, 10(7):927-955.
• Gratton JA, Abraham MH, Bradbury MW, Chadha HS: Molecular factors nfluenc ng drug transfer across the blood-bra n barr er. Journal of Pharmacy and Pharmacology 1997, 49(12):1211-1216.
• Kelder J, Grootenhu s PJ, Bayada D, Delbress ne LC, Ploemen J-P: Polar molecular surface as a dom nat ng determ nant for oral absorpt on and bra n penetrat on of drugs. Pharmaceut cal Research 1999, 16(10):1514-1519.
• L p nsk CA: Drug-l ke propert es and the causes of poor solub l ty and poor permeab l ty. Journal of Pharmacolog cal and Tox colog cal Methods 2000, 44(1):235-249.
• Abraham MH: The factors that nfluence permeat on across the blood–bra n barr er. European Journal of Med c nal Chem stry 2004, 39(3):235-240.
• Fu XC, Wang GP, Shan HL, L ang WQ, Gao JQ: Pred ct ng blood–bra n barr er penetrat on from molecular we ght and number of polar atoms. European Journal of Pharmaceut cs and B opharmaceut cs 2008, 70(2):462-466.
• Pardr dge W: The blood-bra n barr er: Bottleneck n bra n drug development. Neurotherapeut cs 2005, 2(1):3-14.
• Seel g A: The role of s ze and charge for blood–bra n barr er permeat on of drugs and fatty ac ds. Journal of Molecular Neurosc ence 2007, 33(1):32-41.
• H gg ns CF, Gottesman MM: Is the mult drug transporter a fl ppase? Trends n B ochem cal Sc ences 1992, 17(1):18-21.
• Matheny CJ, Lamb MW, Brouwer KLR, Pollack GM: Pharmacok net c and pharmacodynam c mpl cat ons of p-glycoprote n modulat on. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2001, 21(7):778-796.
• K mura Y, Kodan A, Matsuo M, Ueda K: Cholesterol f ll- n model: Mechan sm for substrate recogn t on by ABC prote ns. Journal of B oenerget cs and B omembranes 2007, 39(5-6):447-452.
• Th ebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, W ll ngham MC: Immunoh stochem cal local zat on n normal t ssues of d fferent ep topes n the mult drug transport prote n P170: Ev dence for local zat on n bra n cap llar es and crossreact v ty of one ant body w th a muscle prote n. Journal of H stochem stry & Cytochem stry 1989, 37(2):159-164.
• Tsuj A, Terasak T, Takabatake Y, Tenda Y, Tama I, Yamash ma T, et al: P-glycoprote n as the drug efflux pump n pr mary cultured bov ne bra n cap llary endothel al cells. L fe Sc ences 1992, 51(18):1427-1437.
• Löscher W, Potschka H: Role of drug efflux transporters n the bra n for drug d spos t on and treatment of bra n d seases. Progress n Neurob ology 2005, 76(1):22-76.
• Jardetzky O: S mple alloster c model for membrane pumps. Nature 1966, 211(5052):969-970.
• Sa er MH: A Funct onal-phylogenet c class f cat on system for transmembrane solute transporters. M crob ology and Molecular B ology Rev ews 2000, 64(2):354-411.
• Forrest LR, Krämer R, Z egler C: The structural bas s of secondary act ve transport mechan sms. B och m ca et B ophys ca Acta (BBA)-B oenerget cs 2011, 1807(2):167-188.
• Schless nger A, Khur N, G acom n KM, Sal A: Molecular model ng and l gand dock ng for solute carr er (SLC) transporters. Current Top cs n Med c nal Chem stry 2013, 13(7):843-856.
• X e R, Bouw MR, Hammarlund‐Udenaes M: Modell ng of the blood‐bra n barr er transport of morph ne‐3‐glucuron de stud ed us ng m crod alys s n the rat: Involvement of probenec d‐ sens t ve transport. Br t sh Journal of Pharmacology 2000, 131(8):1784-1792. Mensch J, Oyarzabal J, Mack e C, August jns P: In v vo, n v tro and n s l co methods for small 102. molecule transfer across the BBB. Journal of Pharmaceut cal Sc ences 2009, 98(12): 4429-4468.
• Patlak CS, Blasberg RG, Fenstermacher JD: Graph cal evaluat on of blood-to-bra n transfer constants from mult ple-t me uptake data. Journal of Cerebral Blood Flow & Metabol sm 1983, 3(1):1-7.
• Takasato Y, Rapoport SI, Sm th QR: An n s tu bra n perfus on techn que to study cerebrovascular transport n the rat. Amer can Journal of Phys ology-Heart and C rculatory Phys ology 1984, 247(3):484-493.
• Sm th QR. A Rev ew of Blood-Bra n Barr er Transport Techn ques. In: Nag S (eds), The Blood- Bra n Barr er: B ology and Research Protocols. Humana Press, New York C ty, USA. 2003:193-208.
• Zhao R, Kalvass JC, Pollack G: Assessment of blood–bra n barr er permeab l ty us ng the n s tu mouse bra n perfus on techn que. Pharmaceut cal Research 2009, 26(7):1657-1664.
• Dagena s C, Avdeef A, Ts nman O, Dudley A, Bel veau R: P-glycoprote n def c ent mouse n s tu blood-bra n barr er permeab l ty and ts pred ct on us ng an n combo PAMPA model. European Journal of Pharmaceut cal Sc ences 2009, 38(2):121-137.
• Oldendorf WH: Measurement of bra n uptake of rad olabeled substances us ng a tr t ated water nternal standard. Bra n Research 1970, 24(2):372-376.
• Gross P, Spos to N, Pettersen S, Fenstermacher J: D fferences n funct on and structure of the cap llary endothel um n gray matter, wh te matter and a c rcumventr cular organ of rat bra n. Journal of Vascular Research 1986, 23(6):261-270.
• Hammarlund-Udenaes M: The use of m crod alys s n CNS drug del very stud es: Pharmacok net c perspect ves and results w th analges cs and ant ep lept cs. Advanced Drug Del very Rev ews 2000, 45(2):283-294.
• Benven ste H, Hütteme er PC: M crod alys s—theory and appl cat on. Progress n Neurob ology de Lange EC, Danhof M, de Boer AG, Bre mer DD: Methodolog cal cons derat ons of ntracerebral m crod alys s n pharmacok net c stud es on drug transport across the blood–bra n barr er. Bra n Research Rev ews 1997, 25(1):27-49.
• de Lange EC, De Boer A, Bre mer DD: Methodolog cal ssues n m crod alys s sampl ng for pharmacok net c stud es. Advanced Drug Del very Rev ews 2000, 45(2):125-148.
• de Lange EC, de Boer BA, Bre mer DD: M crod alys s for pharmacok net c analys s of drug transport to the bra n. Advanced Drug Del very Rev ews 1999, 36(2):211-227.
• Elmqu st WF, Sawchuk RJ: Appl cat on of m crod alys s n pharmacok net c stud es. Pharmaceut cal Research 1997, 14(3):267-288.
• Kehr J: A survey on quant tat ve m crod alys s: Theoret cal models and pract cal mpl cat ons. Journal of Neurosc ence Methods 1993, 48(3):251-261.
• Oldendorf WH: L p d solub l ty and drug penetrat on of the blood bra n barr er. Exper mental B ology and Med c ne 1974, 147(3):813-816.
• Pardr dge WM: K net cs of compet t ve nh b t on of neutral am no ac d transport across the blood-bra n barr er. Journal of Neurochem stry 1977, 28(1):103-108.
• Kakee A, Terasak T, Sug yama Y: Bra n efflux ndex as a novel method of analyz ng efflux transport at the blood-bra n barr er. Journal of Pharmacology and Exper mental Therapeut cs 1996, 277(3):1550-1559.
• Wang Y, Sawchuk RJ: Z dovud ne transport n the rabb t bra n dur ng ntravenous and ntracerebroventr cular nfus on. Journal of Pharmaceut cal Sc ences 1995, 84(7):871-876.
• Wang Y, Welty DR: The s multaneous est mat on of the nflux and efflux blood-bra n barr er permeab l t es of gabapent n us ng a m crod alys s-pharmacok net c approach. Pharmaceut cal Research 1996, 13(3):398-403.
• Deguch Y, Nozawa K, Yamada S, Yokoyama Y, K mura R: Quant tat ve evaluat on of bra n d str but on and blood-bra n barr er efflux transport of probenec d n rats by m crod alys s: Poss ble nvolvement of the monocarboxyl c ac d transport system. Journal of Pharmacology and Exper mental Therapeut cs 1997, 280(2):551-560.
• Deguch Y, Inabe K, Tom yasu K, Nozawa K, Yamada S, K mura R: Study on bra n nterst t al flu d d str but on and blood-bra n barr er transport of baclofen n rats by m crod alys s. Pharmaceut cal Research 1995, 12(12):1838-1844.
• Deguch Y, Yokoyama Y, Sakamoto T, Hayash H, Na to T, Yamada S, et al: Bra n d str but on of 6-mercaptopur ne s regulated by the efflux transport system n the blood-bra n barr er 1. L fe Sc ences 2000, 66(7):649-662.
• Bouw MR, Gårdmark M, Hammarlund-Udenaes M: Pharmacok net c-pharmacodynam c modell ng of morph ne transport across the blood-bra n barr er as a cause of the ant noc cept ve effect delay n rats—a m crod alys s study. Pharmaceut cal Research 2000, 17(10):1220-1227.
• Tunblad K, Hammarlund-Udenaes M, Jonsson EN: Influence of probenec d on the del very of morph ne-6-glucuron de to the bra n. European Journal of Pharmaceut cal Sc ences 2005, 24(1):49-57.
• Boström E, S monsson US, Hammarlund-Udenaes M: In v vo blood-bra n barr er transport of oxycodone n the rat: Ind cat ons for act ve nflux and mpl cat ons for pharmacok net cs/ pharmacodynam cs. Drug Metabol sm and D spos t on 2006, 34(9):1624-1631.
• Tunblad K, Hammarlund-Udenaes M, Jonsson EN: An ntegrated model for the analys s of pharmacok net c data from m crod alys s exper ments. Pharmaceut cal Research 2004, 21(9):1698-1707.
• Dagena s C, Rousselle C, Pollack GM, Scherrmann J-M: Development of an n s tu mouse bra n perfus on model and ts appl cat on to mdr1a p-glycoprote n-def c ent m ce. Journal of Cerebral Blood Flow & Metabol sm 2000, 20(2):381-386.
• L u X, Tu M, Kelly RS, Chen C, Sm th BJ: Development of a computat onal approach to pred ct blood-bra n barr er permeab l ty. Drug Metabol sm and D spos t on 2004, 32(1):132-139.
• Crone C: The permeab l ty of cap llar es n var ous organs as determ ned by use of the ‘Ind cator D ffus on’ method. Acta Phys olog ca Scand nav ca 1963, 58(4):292-305.
• Sm th Q, Samala R: In S tu and In V vo An mal Models. In: Hammarlund-Udenaes M, de Lange ECM, Thorne RG (eds), Drug Del very to the Bra n. Spr nger, Berl n, Germany. 2014:199-211.
• Poul n P, The l FP: Pred ct on of pharmacok net cs pr or to n v vo stud es. 1. Mechan sm-based pred ct on of volume of d str but on. Journal of Pharmaceut cal Sc ences 2002, 91(1):129-156.
• Poul n P, The l FP: Pred ct on of pharmacok net cs pr or to In V vo stud es. II. Gener c phys olog cally based pharmacok net c models of drug d spos t on. Journal of Pharmaceut cal Sc ences 2002, 91(5):1358-1370.
• Rodgers T, Leahy D, Rowland M: Phys olog cally based pharmacok net c model ng 1: Pred ct ng the t ssue d str but on of moderate-to-strong bases. Journal of Pharmaceut cal Sc ences 2005, 94(6):1259-1276.
• Rodgers T, Rowland M: Phys olog cally based pharmacok net c modell ng 2: Pred ct ng the t ssue d str but on of ac ds, very weak bases, neutrals and zw tter ons. Journal of Pharmaceut cal Sc ences 2006, 95(6):1238-1257.
• Krämer SD, Lombard D, Pr morac A, Thomae AV, Wunderl -Allenspach H: L p d-b layer permeat on of drug-l ke compounds. Chem stry & B od vers ty 2009, 6(11):1900-1916.
• Qu gnot N: Model ng b oava lab l ty to organs protected by b olog cal barr ers. In S l co Pharmacology 2013, 1(1):1-9.
• W lhelm I, Kr zba IA: In v tro models of the blood–bra n barr er for the study of drug del very to the bra n. Molecular Pharmaceut cs 2014, 11(7):1949-1963.
• Abbott NJ, Dolman DE, Yusof SR, Re chel A. In V tro Models of CNS Barr ers. In: Hammarlund- Udenaes M, de Lange ECM, Thorne RG (eds), Drug Del very to the Bra n. Spr nger, Berl n, Germany. 2014:163-197.
• D L, Kerns EH, Bezar IF, Petusky SL, Huang Y: Compar son of blood–bra n barr er permeab l ty assays: In s tu bra n perfus on, MDR1-MDCKII and PAMPA-BBB. Journal of Pharmaceut cal Sc ences 2009, 98(6):1980-1991.
• B ckel U: How to measure drug transport across the blood-bra n barr er. Neurotherapeut cs 2005, 2(1):15-26.
• Lev n VA: Relat onsh p of octanol/water part t on coeff c ent and molecular we ght to rat bra n cap llary permeab l ty. Journal of Med c nal Chem stry 1980, 23(6):682-684.
• Fr dén M, W n warter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, et al: Structure−bra n exposure relat onsh ps n rat and human us ng a novel data set of unbound drug concentrat ons n bra n nterst t al and cerebrosp nal flu ds. Journal of Med c nal Chem stry 2009, 52(20):6233-6243.
• Fan Y, Unwalla R, Denny RA, D L, Kerns EH, D ller DJ, et al: Ins ghts for pred ct ng blood- bra n barr er penetrat on of CNS targeted molecules us ng QSPR approaches. Journal of Chem cal Informat on and Model ng 2010, 50(6):1123-1133.
• Mensch J, Jaroskova L, Sanderson W, Mel s A, Mack e C, Verreck G, et al: Appl cat on of PAMPA-models to pred ct BBB permeab l ty nclud ng efflux rat o, plasma prote n b nd ng and phys cochem cal parameters. Internat onal Journal of Pharmaceut cs 2010, 395(1–2):182-197.
• Mensch J, Mel s A, Mack e C, Verreck G, Brewster ME, August jns P: Evaluat on of var ous PAMPA models to dent fy the most d scr m nat ng method for the pred ct on of BBB permeab l ty. European Journal of Pharmaceut cs and B opharmaceut cs 2010, 74(3):495-502.
• Avdeef A: How well can n v tro bra n m crocap llary endothel al cell models pred ct rodent n v vo blood–bra n barr er permeab l ty? European Journal of Pharmaceut cal Sc ences 2011, 43(3):109-124.
• Avdeef A, Sun N: A new n s tu bra n perfus on flow correct on method for l poph l c drugs based on the pH-dependent Crone-Renk n Equat on. Pharmaceut cal Research 2011, 28(3):517-530.
• Chen H, W n warter S, Fr dén M, Antonsson M, Engkv st O: In s l co pred ct on of unbound bra n-to-plasma concentrat on rat o us ng mach ne learn ng algor thms. Journal of Molecular Graph cs and Modell ng 2011, 29(8):985-995.
• Broccatell F, Larreg eu CA, Cruc an G, Oprea TI, Benet LZ: Improv ng the pred ct on of the bra n d spos t on for orally adm n stered drugs us ng BDDCS. Advanced Drug Del very Rev ews 2012, 64(1):95-109.
• D L, Artursson P, Avdeef A, Ecker GF, Faller B, F scher H, et al: Ev dence-based approach to assess pass ve d ffus on and carr er-med ated drug transport. Drug D scovery Today 2012, 17(15– 16):905-912.
• Lanevsk j K, Japertas P, D dz apetr s R: Improv ng the pred ct on of drug d spos t on n the bra n. Expert Op n on on Drug Metabol sm & Tox cology 2013, 9(4):473-486.
• Jouyban A, Soma eh S. Blood bra n barr er permeat on. In: Acree W (eds), Tox c ty and Drug Test ng. InTech, R jeka, Croat a. 2012:3-24.
• Pardr dge WM: Log(BB), PS products and n s l co models of drug bra n penetrat on. Drug D scovery Today 2004, 9(9):392-393.
• Kalvass JC, Olson ER, Cass dy MP, Selley DE, Pollack GM: Pharmacok net cs and pharmacodynam cs of seven op o ds n p-glycoprote n-competent m ce: Assessment of unbound bra n EC50,u and correlat on of n v tro, precl n cal, and cl n cal data. Journal of Pharmacology and Exper mental Therapeut cs 2007, 323(1):346-355.
• Watson J, Wr ght S, Lucas A, Clarke KL, V ggers J, Cheetham S, et al: Receptor occupancy and bra n free fract on. Drug Metabol sm and D spos t on 2009, 37(4):753-760.
• Fr dén M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M: In v tro methods for est mat ng unbound drug concentrat ons n the bra n nterst t al and ntracellular flu ds. Drug Metabol sm and D spos t on 2007, 35(9):1711-1719.
• Redz c Z: Molecular b ology of the blood-bra n and the blood-cerebrosp nal flu d barr ers: S m lar t es and d fferences. Flu ds and Barr ers of the CNS 2011, 8(1):3.
• Gründer G, H emke C, Paulzen M, Vesel nov c T, Vernaleken I: Therapeut c plasma concentrat ons of ant depressants and ant psychot cs: Lessons from PET mag ng. Pharmacopsych atry 2011, 44(6):236-248.
• Summerf eld SG, Jeffrey P: In v tro pred ct on of bra n penetrat on – a case for free th nk ng? Expert Op n on on Drug D scovery 2006, 1(6):595-607.
• Jeffrey P, Summerf eld S: Assessment of the blood–bra n barr er n CNS drug d scovery. Neurob ology of D sease 2010, 37(1):33-37.
• Doğan SS, Çaban S,Çapan Y: Bra n drug target ng strateg es. Hacettepe Un vers ty Journal of Faculty of Pharmacy 2013, 33(2):231-250.
• Cory Kalvass J, Maurer TS: Influence of nonspec f c bra n and plasma b nd ng on CNS exposure: Impl cat ons for rat onal drug d scovery. B opharmaceut cs & Drug D spos t on 2002, 23(8):327-338.
• Maurer TS, DeBartolo DB, Tess DA, Scott DO: Relat onsh p between exposure and nonspec f c b nd ng of th rty-three central nervous system drugs n m ce. Drug Metabol sm and D spos t on 2005, 33(1):175-181.
• Fr dén M, Bergström F, Wan H, Rehngren M, Ahl n G, Hammarlund-Udenaes M, et al: Measurement of unbound drug exposure n bra n: Model ng of pH part t on ng expla ns d verg ng results between the bra n sl ce and bra n homogenate methods. Drug Metabol sm and D spos t on 2011, 39(3):353-362.
• Gupta A, Chatela n P, Mass ngham R, Jonsson EN, Hammarlund-Udenaes M: Bra n d str but on of cet r z ne enant omers: Compar son of three d fferent t ssue-to-part t on coeff c ents: Kp,Kp,u, and Kp,uu. Drug Metabol sm and D spos t on 2006, 34(2):318-323.
• Cserr HF, Cooper DN, M lhorat TH: Flow of cerebral nterst t al flu d as nd cated by the removal of extracellular markers from rat caudate nucleus. Exper mental Eye Research 1977, 25 (Supplement 1):461-473.
• Rosenberg GA, Kyner WT, Estrada E: Bulk flow of bra n nterst t al flu d under normal and hyperosmolar cond t ons. Amer can Journal of Phys ology-Renal Phys ology 1980, 238(1):42-49.
• Cserr HF, Patlak CS. Secret on and Bulk Flow of Interst t al Flu d. In: Bradbury MB(eds), Phys ology and Pharmacology of the Blood-Bra n Barr er. Spr nger, Berl n, Germany. 1992:245-261.
• Jeffrey P, Summerf eld SG: Challenges for blood-bra n barr er (BBB) screen ng. Xenob ot ca 2007, 37(10/11):1135-1151.
• Fr dén M, Ducrozet F, M ddleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M: Development of a h gh-throughput bra n sl ce method for study ng drug d str but on n the central nervous system. Drug Metabol sm and D spos t on 2009, 37(6):1226-1233.
• Fr dén M, Ljungqv st H, M ddleton B, Bredberg U, Hammarlund-Udenaes M: Improved measurement of drug exposure n the bra n us ng drug-spec f c correct on for res dual blood. Journal of Cerebral Blood Flow & Metabol sm 2010, 30(1):150-161.
• N cholson C, Ph ll ps JM: Ion d ffus on mod f ed by tortuos ty and volume fract on n the extracellular m croenv ronment of the rat cerebellum. The Journal of Phys ology 1981, 321(1):225-257.
• N cholson C, Syková E: Extracellular space structure revealed by d ffus on analys s. Trends n Neurosc ences 1998, 21(5):207-215.
• Becker S, L u X: Evaluat on of the ut l ty of bra n sl ce methods to study bra n penetrat on. Drug Metabol sm and D spos t on 2006, 34(5):855-861.
• Loryan I, Hammarlund-Udenaes M. Drug D scovery Methods for Study ng Bra n Drug Del very and D str but on. In: Hammarlund-Udenaes M, de Lange ECM, Thorne RG (eds), Drug Del very to the Bra n. Spr nger, Berl n, Germany. 2014:271-316.
• D L, Umland JP, Chang G, Huang Y, L n Z, Scott DO, et al: Spec es ndependence n bra n t ssue b nd ng us ng bra n homogenates. Drug Metabol sm and D spos t on 2011, 39(7):1270-1277.
• L u X, Van Natta K, Yeo H, V lensk O, Weller PE, Worboys PD, et al: Unbound drug concentrat on n bra n homogenate and cerebral sp nal flu d at steady state as a surrogate for unbound concentrat on n bra n nterst t al flu d. Drug Metabol sm and D spos t on 2009, 37(4):787-793.
• K elbasa W, Stratford RE: Exploratory translat onal model ng approach n drug development to pred ct human bra n pharmacok net cs and pharmacolog cally relevant cl n cal doses. Drug Metabol sm and D spos t on 2012, 40(5):877-883.
• Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X: Development of a phys olog cally based pharmacok net c model for the rat central nervous system and determ nat on of an n v tro– n v vo scal ng methodology for the blood–bra n barr er permeab l ty of two transporter substrates, morph ne and oxycodone. Journal of Pharmaceut cal Sc ences 2012, 101(11):4277-4292.